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Abstract 
 
Photodynamic therapy is a relatively new treatment for various cancers and other diseases using 
a photosensistiser that produces cytotoxic singlet oxygen (
1
O2) after light irradiation. Current 
approved photosensitisers have limitations, such as a low extinction coefficient in the desired 
therapeutic wavelength of absorption (600 – 900 nm), as in the case of Photofrin®.  The 
discovery of improved photosensitisers is essential if photodynamic therapy is to become more 
common and successful than other treatments. In this research a selection of aza-
dipyrromethenes and their intermediates were synthesised to create photosensitisers that were 
able to absorb light within the therapeutic wavelength and create 
1
O2 by energy transfer from the 
photosensitiser. As shown by others, receptors can be used to control 
1
O2 generation via 
photoinduced electron transfer (PET). The synthesis of aza-dipyrromethenes using intermediates 
containing pyridine groups and crown ethers was unsuccessfully attempted to create 
photosensitisers with receptors sensitive to environmental factors, such as pH and sodium ion 
concentration, in the hope that such receptors would control 
1
O2
 
generation via PET. Evaluation 
of the synthesised compounds for use as photosensitisers was carried out using a range of light 
sources. Measurement of singlet oxygen generated was carried out using diphenylbenzofuran 
(DPBF), a singlet oxygen scavenger, and the depletion of the absorbance of DPBF used to 
quantify the rate of 
1
O2 generation. Comparison with methylene blue, a known photosensitiser, 
gave a singlet oxygen quantum yield of the compounds to evaluate their efficacy as potential 
photosensitisers. It has been shown from the photophysical data that the synthesised compounds 
in this research absorb within the desired range, (600 – 900 nm), but 1O2 generation is 
insufficient and further modification of the aza-dipyrromethene scaffold is needed to create 
useful photosensitisers for photodynamic therapy.  
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Chapter 1 
Introduction 
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1.1 Photodynamic Therapy Background 
 
With 297,991
[1]
 cases diagnosed in the United Kingdom in 2007, and one in four deaths as a 
direct result of, it is not surprising that Cancer remains one of the most feared topics of today‘s 
society. With over two hundred different types of cancer, it is therefore easy to justify the 
money and time invested by researchers in the medical and scientific community to this cause. 
The treatments for cancer are diverse, not least due to the significant number of different types. 
Treatments include surgery, chemotherapy, radiotherapy, bone marrow and stem cell 
transplants, hormone therapy, alternative therapies and photodynamic therapy (PDT) among 
others. This thesis focuses on utilizing photodynamic therapy as an alternative to the more 
invasive treatments by developing potential new compounds capable of acting as photodynamic 
agents. 
Photodynamic therapy is generally considered to be in its infancy as a cancer treatment with 
many of the most significant advances and important research made in the last three decades. 
However, if we are to consider the concept, of using light combined with a photosensitiser, and 
not the terminology then we discover that PDT has actually been around for over 3000 years. 
The Egyptians, Chinese and Indians have all used photodynamic therapy to treat a number of 
different diseases whereby they would cover the affected area with plant extract and then use 
the sun as the radiation source.
[2]
  
It was only at the turn of the twentieth century when Von Tappeiner and his student Oscar Raab 
[2]
 reported the death of the single celled eukaryotes, paramecium, by acridine that they realised 
the significance of light in the process, the cells only became damaged in the presence of light 
and thus the concept was born. In 1900, Raab reported that acridine dyes killed protozoan 
paramecia that had been exposed to light for 1.5 hours. In contrast, when the experiments were 
repeated in the absence of light, acridine dyes took up to 15 hours to kill paramecia. Von 
Tappeiner et al. later introduced the term ‗photodynamic action‘ to describe the process. This 
group studied a range of dyes and their effects on the treatment of skin disease and tumours. 
3 
 
One particular dye, eosin 1, was used with light to treat a basal cell carcinoma starting the field 
that would become photodynamic therapy.
[2]
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It was, however, to take a number of decades before the knowledge gained from Von Tappenier 
and Raab was applied to the clinical setting. A vast amount of research has been invested in 
PDT between then and now with significant advances made in the mid 1960‘s. An example of 
such research is found in the use of the photosensitiser hematoporphyrin derivative (HpD). In 
1964, Lipson et al. demonstrated that HpD  accumulated preferentially in tumour tissue 
compared to healthy tissue.
[3]
 HpD, formed by the treatment of hematoporphyrin with 5% 
sulphuric acid in acetic acid, is a mixture of porphyrin monomers, dimers and ogliomers linked 
covalently by ether or ester bridges.
[4]
 The hematoporphyrin monomer 2 is a poor 
photosensitiser and seperation of the monomer porphyrins by size-exclusion gel 
chromatography gives more tumour specific ogliomeric fractions.
[5]
 Purified HpD was marketed 
as Photofrin by QLT Phototherapeutics (Vancouver, Canada). Photofrin first received approval 
in Canada in 1993 for the treatment of cervical, bladder and gastric cancers.
[3,4]
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Since then approval has been achieved in a number of countries with the popularity of this non-
invasive technique ever growing. 
PDT is the use of a drug, light and endogenous molecular oxygen to produce a cytotoxic effect 
in the treatment of cancerous and non-cancerous diseases.
[6]
 The principle of PDT is that once 
the drug, called the photosensitiser, is administered it accumulates in the malignant tissue. 
Light, of a wavelength specific to the photosensitiser, is then used to excite the photosensitiser 
which in turn undergoes an energy transfer with molecular ground state oxygen (already present 
in the surrounding environment) to produce singlet oxygen, the principle cytotoxic species.
[6] 
The therapeutic wavelength of light is considered to be between 600 - 900 nm as this allows for 
maximum penetration of tissue while the excitation of the photosensitiser remains energetically 
favourable. The reason for the near-infrared requirement is that light is usually absorbed in the 
dermis region of the skin. In the dermis there are blood chromophores, such as 
hematoporphyrin, that absorb within the visible region of light between 400 - 600 nm so 
therefore light above this wavelength is required for greater transmittance.
[7]
  
The pharmacodynamics of PDT is where cell necrosis occurs by the oxidation of cell organelles, 
nucleotides and membranes by singlet oxygen, generated directly due to the photosensitiser, the 
mechanism for which is further discussed in section (1.2.2.).
[8]
 In contrast to surgery, radiation 
therapy or chemotherapy, PDT offers greater selectivity; malignant tissue can be targeted 
specifically by administering light externally or internally via fibre optic cable directly to that 
region minimising damage to healthy cells. The major side effect from PDT is skin 
photosensitivity, where the patient has to avoid sunlight to prevent inadvertent phototoxic 
reactions until the photosensitiser has cleared from the body.
[6]
 However, when the side effects 
caused by PDT are compared with those from the previously mentioned treatments it is plain to 
see the benefits to be achieved from this course of treatment. The severity and invasive nature of 
surgery, radiation or chemotherapy renders PDT as a non-invasive, patient friendly alternative 
to the treatment of particular types of cancer. 
The research invested in PDT over the last few decades has deepened the understanding and 
potential applications for the therapy, nevertheless there are surprisingly few examples of 
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photosensitisers utilised in the clinical setting. The major and leading photosensitiser was that 
discovered by Lipson, Photofrin
®
, as mentioned previously. Despite its widespread use in North 
America, Europe and Japan, Photofrin
®
 has some major disadvantages. The absorption band 
used clinically to excite the photosensitiser, 630 nm, has a low extinction coefficient, meaning 
there is less energy absorbed  owing to the Beer Lambert Law of A = ε c l (where A = 
absorbance, ε = extinction coefficient, c = photosensitiser concentration and l = path length of 
light beam), and thus has a proportional impact on the phosphorescence emission. Also, 
Photofrin, has a long duration of skin photosensitivity of 2-3 months.
[4] 
Currently there is a need 
for new photosensitisers which have a higher extinction coefficient for an absorption band 
between 600 - 900 nm with faster metabolism to allow for fewer weeks of skin photosensitivity.  
Alternatively, these adverse properties could be prevented with a tumour specific 
photosensistiser, localising within tumour cells, thereby limiting the damage done to healthy 
tissue while at the same time maximising that caused to the diseased cells. 
A successful photosensitiser would therefore have the following six criteria:
 [6] 
(1) Preferential pharmacokinetics, allowing for uptake of the photosensitiser within the tumour 
cell over non-cancerous cells allowing for minimal damage done to healthy cells and 
maximise efficacy of the drug. 
(2) Possess negligible dark toxicity; that is, ensuring the PDT drug candidate should be active 
only when there is a light source of specific wavelength.  
(3) High quantum yield of singlet oxygen; this is a number between one and zero that shows 
how efficiently singlet oxygen is produced per photon absorbed by the photosensitiser.  
(4) The wavelength of light at which the photosensitiser phosphoresces is greater than 600 nm. 
This gives maximum penetration of the tissue (~2.5 cm) while still emitting 
phosphorescence energetic enough to form singlet oxygen.  
(5) High extinction coefficient (ε) at the excitation wavelength, since the extinction coefficient 
is directly proportional to absorbance, a strong absorption equates to more photons of 
energy absorbed and hence a greater singlet oxygen generation.  
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(6) Chemically pure and stable, the pharmacodynamics and pharmacokinetics of the 
photosensitiser will be simplified and clarified if there is only one 
compound/enantiomer present, the photosensitiser must also be stable enough to allow 
for appropriate storage and administration.  
When all the criterion are assessed, it is perhaps not so astonishing that there are few 
photosensitisers currently on the market. However , this is due to change shortly, as there are 
scores of PDT agents currently in various stages of clinical trials.
[9]
  
 
1.2 Mechanism of PDT   
 
When a photosensitiser absorbs a photon (hv) of specific energy, an electron is excited in the 
highest occupied molecular orbital (HOMO) from the ground singlet state (S0) to the lowest 
unoccupied molecular orbital (LUMO), of the excited singlet state (S1) (figure 1).
[10,11]
 Within 
the electronic states there are vibrational energy levels that an electron falls through by 
vibrational relaxation until it reaches the lowest vibrational state. When the electron reaches the 
lowest vibrational state it can potentially fall back to the S0 state by emitting a photon of light, 
however due to vibrational relaxation, this light is of a lower energy than that originally 
absorbed. This emitted light is recorded as fluorescence, the wavelength of fluorescent emission 
is always greater than that of the absorbance due to the wavelength being inversely proportional 
to light energy, energy of a photon = hν = hc/λ (where h = Planck‘s contstant, ν = c/λ, where c = 
speed of light and λ = wavelength). If however the electron undergoes a spin forbidden 
transition or a ‗spin flip‘ and changes multiplicity to become a triplet state, a process known as 
intersystem crossing (ISC), the electron can continue to lose energy to the surroundings and step 
down the vibrational energy ladder of the excited triplet state (T1) until it reaches the lowest 
vibrational energy level where return to the ground state T1→ S0 results in a phosphorescent 
emission.
[12]
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Figure 1. Jablonski diagram illustrating the mechanism of PDT when a photosensitiser absorbs 
a photon. For clarity the vibrational energy levels are omitted. Adapted from Konan et al.
[10]
 
 
The lifetime of the T1 state is much longer than the S1 state (in the order of milliseconds as 
opposed to nanoseconds).
[13]
 This is due to the spin-forbidden transition that must occur in order 
for the excited electron to fall from the T1 state to the singlet S0 ground state.
[14]
 When the 
photosensitiser is in the triplet excited state, the photosensitiser can create cytotoxic species by 
two main mechanisms. In the type I mechanism, radicals are produced by hydrogen abstraction 
or electron transfer of biomolecules that collide with the photosensitiser.
[4]
 In the type II 
mechanism an energy transfer between molecular oxygen produces singlet oxygen by 
collisional transfer of the photosensitiser in the T1 state. Both the radicals and singlet oxygen 
then oxidize surrounding biomolecules causing cell death. The photosensitiser can then absorb 
another photon and continue to participate in type I and type II mechanisms as long as it is not 
destroyed by photobleaching.     
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1.2.1 Multiplicity of Molecular Oxygen 
 
Multiplicity is determined by the following equation, multiplicity = 2S + 1 (where S = spin 
angular momentum a value of ± 1/2 for each unpaired electron). If two electrons occupied the 
same orbital their spins would cancel each other out, S = 2 [½ + (-½)] +1 = 1, so the multiplicity 
is a singlet state. In molecular oxygen, there are two unpaired electrons in the ground state 
electron configuration. Using the equation above S = 2(1) + 1 so S = 3, hence molecular oxygen 
ground state is triplet (Figure 2).  
                     
O2 triplet O2 singlet
2s
2p
S = 3 S = 1
2p
2s
 
 Figure 2. Multiplicities of ground triplet state and excited singlet state oxygen 
 
The ground triplet state (T0) oxygen and the excited singlet state (S1) oxygen are energetically 
and magnetically different. The T0 state oxygen is paramagnetic due to two unpaired electrons in 
degenerate orbitals with the same spin, whereas the S1 state oxygen is diamagnetic due to paired 
electrons in the same orbital. The energy difference between the two states is 94 kJ/mol since  
the S1 state is more energetically unfavourable due to the pairing energy that is required to have 
two electrons in the same orbital.
[15] 
In PDT the S1 state oxygen is created by the spin flip of an 
electron in the T0 state oxygen by energy transfer of photosensitiser in the T1 state.  
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1.2.2 Methods for Determining Photocytotoxicity 
 
In PDT, photocytotoxicity can be caused by two quite distinct mechanisms, namely Type I and 
Type II. The generation of singlet oxygen (
1
O2) is known as Type II whereas in the Type I 
mechanism; hydroxyl radicals (OH
.
) and super oxide anions (O2
-
) are the reactive species 
produced. It may be that in PDT the cytotoxicity is caused by either one of the mechanisms or a 
combination of both. Dougherty et. al. have shown that by using a singlet oxygen quencher, 1,3-
diphenylisobenzofuran 3,  the cytotoxic effect could be attributed to singlet oxygen when 
haematoporphyrin derivative was used as a photosensitiser.
[16] 
Diphenylisobenzofuran has an 
absorbance at 410 nm that decreases upon reaction with singlet oxygen. The rate of the 
disappearance of this band also gives a method for determining how efficiently the 
photosensitiser can generate singlet oxygen.  
 
                                             
O
Ph
Ph
3  
Sodium azide (NaN3), a 
1
O2 quencher, and D-mannitol, a OH
. 
scavenger, has been used to 
determine the dominant mechanism of photocytotoxicity when using HeLa cells incubated with 
a photosensitiser.
[17] 
HeLa cells
 
in the presence of either NaN3 or D-mannitol were 
photoirradiated and the % cell survival taken after 24 h incubation. HeLa cells incubated with 
NaN3 showed the highest % cell survival, indicating photocytoxicity was no longer inhibited 
and 
1
O2 generation was the dominant mechanism of photocytotoxicity.  
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1.3 Light Sources for Photodynamic Therapy 
 
There are a number of various light sources available clinically for PDT, of which there are two 
main groups- lasers and lamps. In general, laser light sources are beneficial for endoscopic 
treatment as they can be coupled to fibre optic cables. Conversely the lamp light source does not 
have sufficient power for irradiation when coupled to fibre optic cables so the use of lamps are 
limited to superficial lesions.
[18] 
Laser light sources produce monochromatic light so that in 
some cases a different laser light source is needed to compensate the different absorption 
maxima between various photosensitisers. It may be the case that there is no advantage to be 
gained from monochromatic light sources since lamps, which have a broad spectrum of light 
wavelength, can be tuned to emit within the required wavelength with the use of filters. This 
means that some lamp light sources can provide excitation for 5-aminolevulinic acid (ALA), 
Foscan and hematoporphyrin.
[18]
 Future light sources may be the use of light emitting diodes 
(LED) and femtosecond solid state lasers. The LED would give a choice of wavelengths from 
350 - 1100 nm, covering the absorption maxima of all currently approved photosensitisers. The 
use of femtosecond solid state lasers would exploit two-photon excitation, where two photons of 
the same energy are able to excite an electron in the photosensitiser to an energy level that is the 
sum of the two photons‘ energy. This means that light in the near infra-red region, for example 
800 nm, could be used to excite a photosensitiser the has an absorption maxima at around 400 
nm, allowing for increased penetration of tissue.
[8]
 
 
1.4 Second Generation Photosensitisers 
 
Due to the low absorption bands of HpD and Photofrin at therapeutic wavelengths (600 - 800 
nm), high photosensitivity and other disadvantages associated with these photosensitiers, 
research has focused on the development of new ‗second generation‘ photosensitisers.    
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Foscan (meso-tetrahydroxyphenylchlorin, m-THPC, temoporfin) 4 has shown greater PDT 
results in treatment of rats with mammary carcinoma than its corresponding porphyrin (m-
THPP) or Photofrin.
[19] 
At a 4 times lower concentration, m-THPC has a higher absorbance than 
m-THPP at 652 nm. There is a preferential uptake of m-THPC in the skin over tumour cells but 
this does not hinder the efficacy of the treatment and damage of the tumour occurs around the 
vasculature and neoplastic cells where the photosensitiser is uptaken. When tumour regrowth 
was measured the tumour doubled in size after 2 days when treated with m-THPP or Photofrin 
but exponential growth did not occur until 12 days after treatment with m-THPC at a 10 times 
lower concentration than Photofrin.
[20]
  
Skin cancers such as basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and actinic 
keratosis (thought to be pre-malignant form of squamous cell carcinoma) are optimal for 
treatment with PDT. Since cancers of this type are superficial, light can be focused on the region 
where the lesions are, minimising damage to healthy cells. Alternatively, the problem of 
selective uptake of a photosensitiser in a tumour could be avoided since the photosensitiser can 
be topically applied to the lesion rather than injected into the blood stream. Foscan was used in 
a clinical study in 1999 for the treatment of BCC and SCC lesions in the head and neck 
region.
[21]
 The irradiation is within the therapeutic window at 652 nm and effective at a light 
source of energy 5 - 20 J/cm
2
 with skin photosensitivity of 2 weeks. Tumour necrosis was 
visible after 48 h in all the lesions treated, 88 BCC lesions in 14 patients and 9 SCC lesions in 4 
patients, with a complete response rate of 92 % for BCC patients and 100 % for SCC patients.
 
Foscan was approved in October 2001 for use in the European Union, Iceland & Norway for 
treatment of head and neck cancer. 
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ALA 5 induces the production of protoporphyrin IX (PpIX) 6 in the haeme pathway of the 
mitochondria (Figure 3).
[22]
 Haeme is a precursor to haemeproteins such as haemoglobin, 
myoglobin and cytochromes. The conversion of PpIX to haeme through a series of pathways 
has a rate-determining step, the addition of iron by the enzyme ferrochelatase.
[22]
 In tumour cells 
where there is faster proliferation, and ferrochelatase is inhibited, the addition of ALA causes 
PpIX to build up rapidly. Since ALA is hydrophobic, alkyl-esters were created to improve 
lipophilicity and increase uptake of the drug across the membrane to give a higher endogenous 
PpIX concentration at lower concentrations than ALA.
[23] 
In contrast to structural changes of 
ALA, the importance of the mode of drug delivery has been shown when a higher concentration 
of ALA over ester derivatives methyl-ALA and hexyl-ALA was observed by using a 
bioadhesive-patch based system in porcine skin.
[24]
 Currently in Europe and Australia the 
methyl-ester of ALA, Metvix developed by Photocure, is approved for treatment of actinic 
keratosis and basal cell carcinoma.
[22]
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Figure 3. Simplified Scheme showing PpIX 6 is produced from ALA 5 
 
Light intensity, length of time of irradiation, number of treatments and wavelength of light are 
some of the variables that alter the results of treatment in PDT by ALA.  One study showed that 
it was possible to use light of a lower intensity to achieve a complete response of 84 % for 
patients with basal cell carcinoma.
[25]
 When lesions were illuminated with light of intensity 45 J 
/ cm
2 
twice, with a period of 2 h between first and second illumination, efficacy was greater than 
if a single illumination had been used at a much higher intensity.
 
 Protoporphyrin IX (PpIX) has 
an absorption maximum at 410 nm. Blue light has a closer wavelength than red light to this 
absorption maximum and light administered at 417 nm successfully treated actinic keratosis. 
[22, 
26]
 This is due to blue light being a more efficient activator for PpIX and actinic keratosis occurs 
in the epidermis so light does not have to penetrate deep to excite PpIX.
[27] 
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1.4.1 Addition of Receptors and Photoinduced Electron Transfer (PET) 
 
As previously mentioned, phosphorescence or fluorescence is emitted when an electron in an 
excited state of the photosensitiser falls back down to the ground state via a radiational pathway. 
Photoinduced electron transfer (PET) can quench these emissions by the donation of an electron 
from a covalently attached donor atom. This redox process must be energetically favourable 
allowing for the reduction of the photosensitiser entity and therefore quenching the emission by 
replacing the excited electron while the donor moiety can accept the electron in the excited state 
of the photosensitiser by back donation.
[28] 
This process is illustrated in Figure 4. 
 
 
 
 
 
 
 
Figure 4. Frontier orbital diagram displaying a two component system illustrating the potential 
electron transfer occurring in a PET system designed to quench emission. 
 
The use of PET provides a potential mechanism for control over when a molecule will or will 
not emit phosphorescence or fluorescence. In PDT this control would be beneficial if 
phosphorescence could be switched ―on‖ only when the photosensitiser was in a tumour cell but 
―off‖ in healthy tissue. The diagram below (Figure 5) shows two photophysical pathways. The 
first pathway has a receptor which is unbound and the lone pair of electrons are energetically 
favourable to quench the emission of the photosensitiser by PET. When the receptor is bound by 
the relevant substrate the oxidation potential of the electrons in the highest occupied molecular 
orbital (HOMO) has risen substantially no longer allowing an electron to participate in PET, 
Excited 
Fluorophore 
E 
Free receptor 
LUMO 
HOMO 
HOMO 
PET 
LUMO 
HOMO 
HOMO 
Back ET 
Fluorophore 
radical anion 
Receptor 
radical cation 
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phosphorescence is no longer blocked and singlet oxygen may be produced from the resulting 
phosphorescence emission.   
 
Photosensitiser
Photosensitiser
light 600-900 nm
Phosphorescence
      blocked
O2
1
O2
light 600-900 nm
Phosphorescence
X X
O2
1
O2
X
Unbound receptor
PET
Bound receptor
No PET
Photosensitiser
+ substrate binds
to receptor
Figure 5. PET from receptors influencing photosensitiser phosphorescence generation 
 
Tertiary amines covalently attached to bromonaphthalene derivatives were shown to act as 
phosphorescent pH sensors, where phosphorescence was emitted in acidic conditions.
[29]
 In 
addition to proton receptors, crown ethers are able to act as  phosphorescent metal cation 
sensors (Na
+
,Ca
2+
,K
+
,Mg
2+
).
[30]
 Since tumour sites have a higher concentration of protons and 
metal cations the development of photosensitisers that are only cytotoxic under identical 
environments to cancer sites should help the efficacy of PDT treatment.  
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1.5 Potential Candidates for PDT Drug Structures 
 
Dipyrromethene (DIPY) compounds (7-9) and their analogues are being explored as potential 
photosensitisers for PDT. The core structure of the DIPY compound can incorporate aryl 
substituents with the tetra-aryl moieties being the most common. This extended conjugation 
increases the maximum wavelength of absorption from around λmax= 500 nm for compound 8 to 
greater than λmax = 600 nm as is the case in compound 9. The C-8 carbon of the DIPY 7 can be 
substituted for a nitrogen atom to give aza derivatives, and chelation with boron etherate gives 
aza-borondipyrromethenes (BODIPY) 9.
[31] 
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The use of a boron atom adds rigidity to the structure in 9 minimising a return to the ground 
state of an excited photosensitiser by non-radiative processes such as contact with other 
molecules, allowing for the desired phosphorescence emission.
[32] 
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Addition of electron donating groups on aryl substituents of BODIPY compounds modifies their 
absorbance maximum. Attachment of a methoxy group at the para-position of a 3-aryl 
substituent caused a red-shift in absorbance from λmax= 650 nm to λmax= 688 nm in aza-
BODIPYs 10 (79, 000 M
-1
cm
-1
) and 11 (85,000 M
-1
 cm
-1
).
[31]
 This effect was observed on other 
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BODIPYs, and in contrast an ortho-substituted methoxy group produced a blue shift in 
absorbance. The position of electron donating and withdrawing group may provide a tool for 
―fine tuning‖ the absorbance wavelength in novel photosensitisers.  
Another important parameter for consideration of photosensitiser design is the quantum yield of 
phosphorescence. Halogens and other ‗heavy atoms‘ are able to facilitate inter-system crossing, 
the covalent attachment of iodine to 12 examines the impact of the ‗heavy atom effect‘.[32] The 
quantum efficiency of fluorescence changed from  Фfl = 0.70 in MeOH for 12 (120,000 M
-1
cm
-1
) 
to Фfl = 0.02 for 13 (110,000 M
-1
cm
-1
), this decrease being assigned to an increased quantum 
yield of phosphorescence.  
 
                                    
N N
B
F F
N N
II
B
F F
12 13  
 
The heavy atom effect has been responsible for the higher quantum yield of phosphorescence 
emission seen for the brominated BODIPY compound at a 100 fold lower concentration when 
compared to that of the unbrominated BODIPY analogue compound.
[33] 
In general, the halogen 
needs to be attached to the core structure of the photosensitiser in order to influence internal 
spin-orbit coupling, showing no significant change when attached to an aryl substituent. The 
attachment of either iodine or bromine to the BODIPY derivatives has not significantly altered 
the wavelength of absorbance.
[33,34]
  
The use of receptors that quench phosphorescence by donation of an electron provides an 
additional parameter, allowing for enhanced selectivity in the modification of photosensitisers, 
specifically enabling control over the conditions that singlet oxygen may be produced. The aza-
BODIPY 14 has been synthesised that uses the above mentioned strategies for design of 
effective photosensitisers.
[35]
 In addition to the benefits seen from compound 9, compound 14 
has a methoxy group in the aryl region. This methoxy group causes an increase in the maximum 
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absorbance wavelength, as discussed in compound 11. As well as containing bromine 
covalently attached to the core enhancing the quantum yield of phosphorescence by the heavy 
atom effect, compound 14 also contains a tertiary amine receptor that quenches 
phosphorescence via PET unless the amine is protonated when in an acidic environment. The 
production of singlet oxygen is dependent on the nanoevironment of the photosensitiser 
[36]
. 
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Receptors such as crown ethers and amines are able to show photoinduced electron transfer until 
this process is blocked by a cation such as Ca
2+
 or Na
+
, or a proton. In PDT this is useful since 
the microenvironment of a tumour cell contains higher concentrations of cations at a lower pH. 
This would enable photosensitisers containing such receptors to only become cytotoxic when in 
an environment similar to that of a tumour cell. Following on from this work a BODIPY 
compound has been synthesised that contains two receptors, one for protons and the other for 
sodium ions.
[37]
 This means that both conditions have to be met for phosphorescence to be 
emitted or PET by one or both receptors will quench the photosensitiser. Two receptors greatly 
enhance the selectivity of a photosensitiser and minimise cytotoxic effects towards healthy cells.   
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1.6 Localisation of Photosensitiser in Tumours 
 
 
1.6.1 Liposomes 
 
 
Another benefit of PDT is that regardless of the location of the photosensitiser in tissues light 
can be administered locally at the tumour site and only induce a cytotoxic effect at the area 
where light has penetrated tissue. The previous section looked at the development of 
photosensitisers that switch on and off the production of singlet oxygen depending on their 
micro environment, however photosensitiser modification has also been investigated and shown 
preferential uptake in tumour cells over normal cells thus increasing the efficacy of the 
treatment while minimising side effects by indiscriminate damage to healthy cells.  
Photosensitisers can form conjugates with serum proteins such as albumin and lipoproteins.
[38]
 
Hydrophilic photosensitisers such as tetrasulfonated porphyrins and phthalocyanines were 
discovered to bind to albumin and globulins upon intravenous administration whereas 
hydrophobic photosensitisers show a preference for binding to low density lipoproteins.
[39]
 
Lipoproteins are responsible for transporting hydrophobic molecules such as cholesterol and 
consist of proteins and lipids.
[40]
 Low-density lipoprotein (LDL) contains a higher ratio of lipid 
to protein than high density lipoprotein (HDL) and LDLs are considered to have the biggest 
effect in transport of hydrophobic photosensitisers. Tumour cells have a higher number of LDL 
receptors compared to healthy cells enabling more LDL to be absorbed by endocytosis.
[38] 
In 
addition to the efficacy of treatment with PDT being improved by increased uptake of LDL-
bound photosensitisers in tumours, the highly oxidised liposomes post PDT may contribute to 
an enhanced cytotoxic effect.
[38]
   
Liposomes can be used to encapsulate photosensitisers prior to intravenous infusion. This 
prevents aggregation that would inhibit the ability for the photosensitiser to act as a singlet 
oxygen generator.
[41] 
A study carried out using human U87 glioma implanted in rats, compared 
the  treatment of Photofrin in a liposomal formulation with Photofrin administered in a dextrose 
vehicle.
[42]
 The uptake within the U87 glioma was increased with the liposome formulation, 
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palmitoyldiphosphatidyl-choline (DPPC), destruction of the tumour was enhanced illustrating 
the ability of liposomes to act as carriers. Conventional liposomes such as those made from 
phosphatidylcholines have a poor plasma half-life.  Disintegration occurs by interaction 
between lipoproteins or taken up by macrophages and releasing the photosensitiser they were 
carrying into the blood stream before reaching the tumour site.
[41]
 Modification of the 
conventional liposomes with polyethylene glycol (PEG) can increase the plasma half-life to 12 
h and improve the uptake of the non-aggregated form.
[43] 
There is little variation between the intracellular pH of various tumour cells compared to normal 
tissue cells, around 7.0-7.2 pH.
[44]
 However the interstitial space surrounding the tumor is more 
acidic, creating a pH gradient between the interstitial space and intracellular compartment. If a 
drug is weakly basic or acidic then fewer molecules would be ionized in an environment of low 
pH. Since the molecule would be more lipophilic it would be able to diffuse across the 
membrane and once within the tumour cell dissociation would occur again and the drug would 
become ‗trapped‘.[44] It has been suggested that such a mechanism may influence the uptake of 
dicarboxylic porphyrins, where the ionic species will be in equilibrium with the neutral species 
within the cell, thereby,  providing a path for the photosensitiser to eventually leave the cell.
[42]
 
 
1.6.2 Nanoparticles  
 
Another method for photosensitiser delivery is the decoration or encapsulation with 
nanoparticles. Nanoparticles are less than 1 μm in size which is less than the smallest blood 
capillaries (5 - 6 μm), and generally are made from synthetic polymers or ceramic material.[46] 
Loading nanoparticles with photosensitisers avoids embolism in blood capillaries that may be 
caused by the aggregation of a free photosensitiser. Nanoparticles that have external receptors 
specific to tumor cells cancels the need to incorporate this on the photosensitiser, speeding up 
the synthesis of potential drugs.  
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Two types of nanoparticles can be made: one which is biodegradable and releases the 
photosensitiser or a non-biodegradable nanoparticle where the singlet oxygen is able to diffuse 
through the pores of the nanoparticles and the photosensitiser is not released.
[47]
 
Biodegradable nanoparticles are made from synthetic polymers such as poly (lactic acid) (PLA), 
poly(glycolic acid) (PGA) and their co-polymers poly (lactide-co-glycolide) (PLGA). Varying 
the ratios of the polymers influences the biodegradation rate, affecting how quickly the drug 
will be released. Hydrophobicity is controlled by a higher PLA ratio and hydrophilicity by a 
higher PGA ratio.
[46]
 Controlling the biodegradation rate is important if nanoparticles are to be 
used in PDT since there would need to be sufficient time for accumulation within the tumour. 
Non-biodegradable silica can allow singlet oxygen to diffuse through the pores of the mesh but 
still contain the drug. This is beneficial as a cytotoxic effect can be achieved if the nanoparticle 
is localized at the tumour site, removing the risk of aggregation and deactivation of the 
photosensitiser if it had been released.
[47]
  
A common method to enhance biocompatibility of drugs is to use poly(ethylene glycol) PEG, a 
hydrophilic polymer. PEG is used to coat nanoparticles that are otherwise hydrophobic and 
would be rapidly cleared by phagocytes. This ensures that the nanoparticle can circulate the 
body for a longer amount of time and improve drug delivery.
[43] 
 
1.7 Other Treatments: Boron Neutron Capture therapy (BNCT) 
 
Photosensitisers can be modified to be used in other cancer therapies such as boron neutron 
capture therapy. This form of treatment uses irradiation of a non-radioactive 
10
B atom and 
particles formed from the decay cause the destruction of the tumour.
[48] 
The boron (
10
B) isotope 
can disintegrate into an alpha particle 
4
He nucleus and 
7
Li nucleus post irradiation when it 
absorbs a low energy neutron by the following equation: 
10
B + nth → [
10
B]
*
 → 4He + 7Li where 
the enthalpy of the reaction is equal to  + 2.31 MeV. The 
4
He alpha particle can deliver the 
cytotoxic effect within 10 μm, around the size of a red blood cell, so the treatment is localised in 
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a small area. The synthesis of carborane-substituted photosensitisers, such as 
metallophthalocyanines and porphyrins has been reported.
[49,50]
  
 A porphyrin which was shown to localise preferentially at a tumour can act as a carrier for 
boron neutron capture therapy (BNCT).  A metallophthalocyanine was covalently attached to a 
closo-carborane cage as a potential candidate for BNCT.
[50] 
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1.8 Aims & Objectives  
 
 
The following objectives were investigated to assess whether the synthesised aza-
dipyrromethene compounds would be viable photosensitisers for PDT:  
 
 Synthesise of aza-dipyrromethenes from commercially available reagents.  
 
 Alteration of the aza-dipyrromethenes solubility, degree of conjugation and addition of 
functional groups to potentially enhance the compounds for use as photosensitisers.  
 
 Characterisation of the final products and intermediates to assess exact structure and 
purity of the synthesised compounds.  
 
 Obtain the wavelength of absorbtion of the final products so that the appropriate 
wavelength of excitation can be selected for photophysical experiments. 
 
 Perform photophysical experiments on final products to assess the quantum yield of 
singlet oxygen generation by using a singlet oxygen scavenger, diphenylbenzofuran.  
 
 Compare the results using a known photosensitiser, methylene blue, to assess the 
efficacy of the aza-dipyrromethene compounds as potential photosensitisers.  
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2.1 Photosensitiser Selection 
 
The aim of this thesis was to advance on photosensitiser compounds already available and to 
synthesise highly conjugated compounds which had an absorption maxima above 600 nm to 
allow for deeper tissue penetration of light. By varying the substituent groups on these 
compounds they could then be manipulated to contain functional groups that could decrease 
their hydrophobicity or allow for enhanced selectivity as well as introducing heavy atoms to 
enhance their singlet oxygen generation capabilities. These added parameters would allow for 
enhanced phototsensitiser compounds capable of acting as PDT agents. The chosen targets were 
aza-dipyrromethene (aza-DIPY) moieties which have previously been shown by O‘Shea and 
others 
[33]
 to absorb UV in the red region of visible light. Below are five target compounds, 
compounds 15 - 19 (Figure 6), designed to enhance and advance on the photophyiscal properties 
of the aza-DIPY skeleton to allow for increased potency photosensitiser compounds. Compound 
15, a conjugated aza-DIPY compound has an increased π-conjugated area, ensuring that the π – 
π* electronic transitions are occurring at much longer absorbance wavelengths, nearing the 
infrared region of the electromagnetic spectrum. Compound 15 is the template compound to 
which methoxy substituents were added to attempt to create a more soluble compound 16. 
Target 17, again an analogue of 15 is desired since chelation with boron gives the compound 
extra stability. Targets 18 and 19 have pyridine and crown ether substituents respectively to act 
as receptors that would participate in PET, as previously mentioned, to add control over 
phosphorescence and allow for an extra parameter in the selectivity of photosensitisers to 
tumour cells. Pyridine has been chosen as the receptor in 18 as it can be protonated in weakly 
acidic solutions. Due to the sp
2
 hybridisation of the nitrogen atom – it is considered to be only 
weakly basic. The pKa of the conjugate acid of pyridine is 5.21 and therefore at this pH 50 % of 
the pyridine compound will be ionised – if we move to increase the pH by one log unit to pH 6, 
only approx. 10 % of the compound will be ionised. This change in pH is similar to that found 
in the microenvironment surrounding tumour cells, as discussed previously. Compound 18 
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therefore has the potential to act as a tumour selective photosenstiser. Following the PET 
mechanism, when the compound is protonated no electron transfer will occur between the donor 
and acceptor moiety allowing phosphorescence to occur, whereas when the compound is 
unprotonated, as in the case at higher pH,  electron transfer occurs between the receptor and 
fluorophore ensuring no radiative emission occurs. In a similar fashion, compound 19 also has 
the potential to act as a PET selective photosensitiser, benzo 15-crown 5, as seen in compound 
19, is a known sodium sensor and only when the concentration of sodium ions is at a specific 
level will the emission switch on, indirectly generating singlet oxygen. These two compounds 
have the potential to add another dimension to photosensitisers for use in PDT.  
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2.2 Method of Synthesis 
 
Adopting a method similar to that used by O‘Shea et al.[33] compounds 15 -19 were synthesised 
following the general synthetic scheme shown below (Scheme 1). Three steps were involved in 
the synthesis of the target aza-DIPY compounds. 
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20
21
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2315
 
 
Scheme 1. Generic synthesis of aza-DIPY compounds 
 
 
 
The initial step in the synthesis, Step 1, is an aldol condensation between an aldehyde, 
biphenylcarboxaldehyde 20, and a ketone, acetophenone 21, which leads to the chalcone 22. 
The name ‗aldol‘ comes from the product formed by reacting an aldehyde and base together, 
which has an aldehyde and hydroxyl component. Scheme 2 illustrates the general reaction 
mechanism occurring in an aldol condensation. A base such as sodium hydroxide can be used to 
create an enolate 25 from the ketone 24 which has only one acidic α-proton. This enolate 25 
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then attacks the carbonyl of an aldehyde molecule 26, giving the intermediate 27a which can be 
protonated by the previously released water molecule to give an aldol product 27b.    
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Scheme 2. Aldol reaction mechanism 
 
 
The aldol condensation used in Step 1 of the synthesis, is a common reaction used in organic 
chemistry to form new carbon-carbon bonds, usually between aldehydes and ketones. Post-aldol 
reaction condensation can then occur when an acid or base causes the elimination of water to 
yield an enone product. 
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Scheme 3. Aldol condensation reaction 
 
The aldol condensation follows the above reaction mechanism (Scheme 3). Deprotonation can 
only occur on the ketone 21a, to form an enolate 21b, as the aldehyde 20 does not have an 
available acidic α-proton next to the carbonyl group. Also the ketone 21a has only one α-proton 
so the above aldol condensation is regioselective. This enolate then attacks the electrophilic 
carbonyl group of the more reactive aldehyde 20 to give a 1,3-carbonyl alcohol derivative 28a. 
The hydrogen atom between these two functional groups is highly acidic (pKa ~20) and easily 
deprotonated (by the hydroxyl created by 28a removing a proton from water). Elimination of 
the hydroxyl group from 28b, which ordinarily is unfavourable as a leaving group, gives the 
enone 22. The driving force for this E1cB elimination is the extra stability provided by the 
formation of the alkene. 
The next step in the overall synthesis, Step 2, is a conjugate addition using nitromethane 29a as 
a nucleophile, occurring via a Michael addition reaction (Scheme 4). Nitro groups are more 
electron withdrawing than carbonyl groups and therefore create a greater degree of polarisation 
about the adjacent C atom. This means deprotonation to create the enolate 29b occurs more 
readily and therefore can be achieved using a weaker base, such as diethylamine (DEA).  
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Scheme 4. Nitration mechanism 
 
In the mechanism above, Scheme 4, the enolate 29b is first formed from DEA which can attack 
the Michael acceptor, in this case the enone 22, at the electrophilic β-carbon. Another enolate 
29b can be formed when the intermediate 30 takes a proton from another molecule of 
nitromethane, driving the reaction to give the nitro-ketone 23. 
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2.3 Synthesis of Compounds 
 
2.3.1 Synthesis of Compound 15 
 
As previously discussed in the method of synthesis (Section 2.2), an aldol condensation reaction 
was carried out using NaOH as base at room temperature for 24 h (Scheme 5).  
 
O
O
O
1 eq
1 eq
NaOH, RT 24 h 80%
20
21
22
Scheme 5. Step 1, synthesis of 22 
 
The long reaction time and low temperature were chosen in order to favour the production of the 
desired thermodynamic product rather than the alternative kinetic product (see section 2.4.1). A 
yellow precipitate formed and was dried to give the crude product before being purified by 
crystallisation to remove minor impurities of starting material. The structure was determined 
(see section 2.4.1) to reveal the desired product 22. 
O
O2N
NO2Me
O
DEA, 90 C, 24 h
5 eq
1 eq
86%22 23
Scheme 6. Step 2, synthesis of 23 
 
The synthesis of the second intermediate 23 was carried out using nitromethane as described in 
Scheme 6. This gave a brown sticky product 23 which was dried to give a yield of 86% and was 
fully characterised (see section 2.4.1). 
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Scheme 7. Step 3, synthesis of 15 
 
The final step to achieve the aza-DIPY compound 15 (Scheme 7) was very low yielding 
(~14%). This was reported as the best yielding method for the synthesis of aza-DIPY by O‘Shea 
and no further attempts were made to purify following washing with ethanol. Characterisation is 
difficult due to how insoluble the compound is in various solvents because of the high degree of 
conjugation. Chloroform was found to be the best solvent and the nmr is discussed (2.4.1) the 
mass spectra was obtained and confirms the molecular weight of the desired product.  
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2.3.2 Synthesis of Compound 16 
 
To improve on the issues of insolubility and to attempt to create a photosensitiser with a 
different absorbance maximum an aza-DIPY compound with electron donating groups was 
selected, compound 16. The synthesis was carried out using the same methods as described in 
the reactions in (2.2). Step 1 was the creation of a chalcone 32 similar to compound 22 but with 
an additional ether substituent in the para position of the acetophenone 31. 
O
O
O
1 eq
1 eq
NaOH, RT 24 h
MeO
OMe
20
31
32
Scheme 8. Step 1, synthesis of 32 
 
There was a similar yield of 74% for a yellow precipitate in the first step (Scheme 8), with full 
characterisation carried out as before (2.4.2). 
O
O2N
NO2Me
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Scheme 9. Step 2, synthesis of 33 
 
The nitration afforded a brown solid 33, compound (yield 75%), (scheme 9) and 
characterisation is discussed in (2.4.2).    
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Scheme 10. Step 3, synthesis of 16 
 
The final step was carried out using the product of step 2 (Scheme 9) unpurified and the 
blue/violet solid formed 16 (yield 10%) was washed in ethanol without further purification, 
using the reaction conditions described above (scheme 10). Characterisation is discussed in 
(2.4.2). 
 
2.3.3 Synthesis of Compound 17 
 
Treatment of the aza-DIPY with the lewis acid BF3OEt3 was attempted to try to generate the 
structurally more stable chelate with boron.  
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Scheme 11. Reaction conditions for attempted chelation with boron 
 
This step proved difficult with no conversion of the starting material into product. A 
19
F nmr 
spectrum was taken of the BF3OEt showing a singlet peak at -153 ppm which is the expected 
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chemical shift of the equivalent fluorine atoms. There were no other peaks in this spectrum so 
decomposition of the reagent was ruled out as a possibility for unsuccessful synthesis.  
 
2.3.4 Synthesis of Intermediate for 18 
 
Using the same methods as the previous aldol condensation three intermediates were attempted 
to give a chalcone that contained a pyridine group (Scheme 12). This would lead to a sensitiser 
that contained a pyridine group to try to introduce receptors. 
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Scheme 12. Aldol condensation step with various substrates. 
 
No consumption of starting materials was observed when trying to synthesise the chalcone 45 
from 4-pyridine carboxaldehyde 44. The reaction was attempted using 4-methoxyacetophenone 
to see if the introduction of an activating group on the aromatic ring of the ketone improved the 
reactivity. The methoxy chalcone 46 was not observed. Finally the reaction was attempted using 
a ketone with a pyridine group to give the chalcone 48. There was no consumption of starting 
materials again for this reaction so it was decided to vary the reaction conditions (see Appendix 
1).  
After attempting several different methods,
[51,52,53]
 the chalcone 45 was synthesised and purified 
by column chromatography. There was a very low yield from the reaction so the optimum 
reaction conditions have not been found. See section (2.4.3) for spectra. 
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2.3.5 Synthesis of Intermediate for 19 
 
In addition to the synthesis of initially aza-DIPY compounds that are conjugated enough to 
absorb above 600 nm. The inclusion of receptors was desired to create potentially more useful 
compounds.  
One possible receptor for ions such as Na
+
 or Ca
2+
 is a crown ether. The crown ether should 
quench the phosphorescence in the target molecule by PET when the concentration of these ions 
is low.  
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Scheme 13. Vilsmeier reaction 
 
 
Due to the expense of buying an aldehyde already containing a crown-ether, the Vilsmeier 
reaction was attempted on the benzo 15-crown-5 ether. After several attempts to synthesise
[30]
 
the 4‘-formylbenzo-15-crown-5, with no formylation of the starting material observed by nmr, 
the aldehyde was then bought from Sigma-Aldrich.  
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Scheme 14. Step 1, synthesis of 51 
 
The aldol condensation of the 4‘-formylbenzo-15-crown-5 with acetophenone was attempted 
using the reaction conditions used previously with NaOH at RT for 24 h. The synthesis did not 
give a high yield of crude product. (see 2.4.4.)  
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2.4 Characterisation of Compounds 
 
2.4.1 Characterisation of Compounds Involved in Synthesis of 15 
 
The structure of compound 15 was determined using nmr experiments; 
1
H nmr, 
13
C nmr, COSY, 
HSQC. 
 
The chalcone product of the first reaction consists of an alkene, meaning that there are two 
isomers possible- the (E)-isomer and the (Z)-isomer. The (E)-isomer is the expected isomer 
since the reaction is occurring under thermodynamic conditions i.e. the more stable product is 
expected. Since the (E)-isomer is desired for our synthesis we need to prove that the correct 
isomer has been synthesised. This can be done by comparing the coupling constants of the 
between the two protons.  
                                                                              
O
O
(E)-isomer (Z)-isomer
22
52
 
  
If an (E)-isomer 22 has been formed a trans coupling constant of J = 14-18 Hz would be found 
in the 
1
H nmr spectrum and if a (Z)-isomer 52 had been formed a coupling constant of J = ~8 Hz 
would be expected. From the COSY spectrum (Figure 7) two peaks were found in the aromatic 
region with doublet multiplicity coupling with each other, i and j. (Compound 22 redrawn in 
Figure 8 with specific hydrogens and carbon atoms labeled for ease of view). When the 
coupling constants of these two peaks were measured in the 
1
H nmr spectrum (Figure 10) they 
had identical coupling constants of J = 15.7 Hz indicating the E isomer had been successfully 
synthesised. From the COSY spectrum (Figure 7)  other peaks such as the coupling between the 
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ortho proton m; and the meta n and para o protons can be observed. Using the COSY spectrum 
along with the HSQC spectrum the peaks in the 
1
H nmr (Figure 10) and the 
13
C nmr (Figure 9 
and Table 1) were assigned for 22. 
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Figure 7. COSY spectrum of 22 
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Figure 8. Compound 22 with specific hydrogens labeled a-o for clarity. 
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Figure 9.  
13
C nmr spectrum of 22. 
 
Table1. Chemical shifts of the corresponding peaks shown in Figure 9 
 
 
 
Chemical Shift 
(ppm) 
Carbon atom Chemical Shift 
(ppm) 
Carbon atom 
190.5 k 129.0 a 
144.4 i 128.9 f 
143.3 l 128.6 n 
140.1 d 128.5 m 
138.2 e 127.9 b 
133.8 h 127.6 g 
132.8 o 127.1 c 
  121.9 j 
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Figure 10.  
1
H nmr spectrum of 22 showing the protons in the aromatic region 
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The second intermediate of the reaction scheme was generated by the addition of nitromethane 
to the alkene group, Figure 11.  
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Figure 11. Nitromethane intermediate resulting in the loss of unsaturated bond 
 
This means that the characteristic peaks from the trans coupling of the previous intermediate 22 
will disappear in the aromatic region of the 
1
H nmr spectrum of 23. In addition there shall be 5 
new peaks in the aliphatic region of the spectrum due to non-equivalent protons created by the 
presence of a chiral centre. If there was no chiral centre we would expect to see only 3 peaks 
with a simplified multiplicity e.g. a doublet with an integration of 2H for the CH2NO2 peak. 
 As expected the two peaks corresponding to alkene protons were not observed in the 
aromatic region of the 
1
H nmr spectrum of 23 (nmr spectrum displayed in Figure 13 with 
Compound 23 redrawn in Figure 12 with specific hydrogens labeled for ease of view).  The 
integration of the protons in the aromatic region revealed 14 protons, as expected for the product 
23. In the aliphatic region of the spectrum (Figure 14) there were five peaks. The first two peaks 
at p and p’ corresponded to the CH2NO2 as would be expected due to the strong electronegative 
nitro group that would de-shield the protons on this carbon atom the most. The chiral proton at i 
has a complex multiplicity due to the interaction of 4 neighbouring protons. The last two, 
doublet of doublet peaks j and j’, correspond  to CH2CO. 
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Figure 12. Compound 23 with specific hydrogens labeled i, j, p and m for clarity. 
 
 
 
 
 
 
Figure 13. 
1
H nmr spectrum of 23, showing the aromatic region  
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Figure 14. 
1
H nmr spectrum of 23, showing the aliphatic region 
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Figure 15. COSY spectrum of 23 showing the aliphatic region of the 
1
H nmr  
 
The 
1
H nmr for 15 (Figure 16) showed only 6 multiplet peaks in the aromatic region, as we 
would expect since the compound is completely conjugated. This also indicates that there is no 
substrate 23 and that the peaks that are observed are from a different compound that has been 
synthesised. As 15 is highly conjugated it is very insoluble, but interpretation of the spectrum 
can still be made. The product is symmetrical so we would also expect that the protons at the 
plane of symmetry on the bridging nitrogen would be equivalent, therefore the number of 
protons that we are expecting to see are 15. From the integration of the spectrum, we have 15 
protons, although assignment cannot be made due to the signals appearing as multiplets.  
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Figure 16. 
1
H nmr spectrum of 15  
 
A mass spectrum was also obtained (Figure 17) where the molecular weight of 15 (601.3 Da) 
was observed.  
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Figure 17. Mass spectrum showing a peak for the molecular weight of 15 at 601.3 Da 
 
 
2.4.2 Characterisation of Compounds Involved in Synthesis of 16 
 
As discussed for 22 (2.4.1) the characteristic peak for the product of the first reaction was the 
trans coupling observed in the aromatic region of the 
1
H nmr spectrum. This was also observed 
for the olefinic group in the spectrum of 32 (Figure 19 with Figure 18 showing Compound 32 
with specific hydrogens labeled) in addition to the CH3 singlet peak, p, more downfield in the 
spectrum due to the electronegetivity of the oxygen atom. The full characterisation of 32 was 
determined using nmr experiments in the same way as for 22 and the 
1
H nmr spectrum (Figure 
19) is fully labeled.  
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Figure 18. Compound 32 with each non-equivalent hydrogen atoms labeled for 
characterisation. 
 
 
 
Figure 19. 
1
H nmr spectrum of 32, each proton peak has been assigned and labeled according 
to Figure 18. 
 
The aromatic region of the nmr spectrum of compound 33 (Figure 21), displays the loss of the 
trans protons and the distinctive ortho coupling, m, still remaining. The integration of the 
signals gives 13 aromatic protons as expected for 33, with Figure 20 displaying the labeling 
used in compound 33. 
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Figure 20. Compound 33 with specific hydrogen atoms labeled for identification 
 
 
 
 Figure 21. 
1
H nmr spectrum of 33 highlighting the aromatic region of the spectrum 
 
Figure 22 displays the aliphatic region of the proton nmr for compound 33. As expected, there 
are an increased number of peaks in this region when compared to 32. The reduction of the C-C 
bond at i and j caused by the Michael addition has resulted in the signals for these protons 
increasing in number and shifting upfield, in addition there has been a new C-C bond created 
resulting in a further CH2 group, the hydrogen atoms of which have been assigned the label q. 
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Figure 22. 
1 
H nmr spectrum of  33 highlighting the aliphatic region 
 
 
In the 
1
H nmr of 16 (Figure 23) there are 6 multiplet peaks in the aromatic region again as 
expected and observed in the 
1
H nmr of 15 (Figure 16). The singlet peak at 3.93 ppm 
corresponds to the methoxy protons of 16, having an integration equivalent to 3 protons. The 
integration of the aromatic peaks in Figure 23 shows 14 aromatic protons for 16 this 
corresponds to the 14 equivalent protons expected.  
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Figure 23. 
1
H nmr spectrum of 16  
 
 
2.4.3 Characterisation of 45 
                                   
The 
1
H nmr of 45 was evaluated and the compound determined to be pure. Figure 24 displays 
the structure of compound 45 with the characteristic hydrogen atoms labeled. Figure 25 displays 
the aromatic region of the proton nmr with peaks assigned to the labeled hydrogen‘s h, j and b. 
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Figure 24. Structure of 45 with labeling of specific hydrogen atoms 
 
 
Figure 25. 
1
H nmr spectrum of 45 
 
The molecular weight of compound 45 was determined and as mass spectrum in Figure 26 
displays, the parent m/z peak of 210.2 Da shows the most abundant peak as that of the 
molecular weight of 45 plus one.  
h 
j 
b 
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Figure 26. Mass spectrum of 45  
 
2.4.4 Characterisation of Compound 51 
 
The 
1
H nmr of 51, Figure 27, indicates that the aldehyde proton from the starting material is no 
longer present in the spectrum of 51. This suggests that one of the starting materials has been 
consumed in the reaction. However, the spectrum is not detailed enough to confirm the structure 
of the product as 51. When the mass of the compound was determined, Figure 28, the mass 
spectrum shows the major peak as the molecular weight of 51 plus a proton (m/z 399 Da), 
indicating that 51 has been synthesized but will need to be purified before further synthesis can 
done. 
M+. + H+ 
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Figure 27. 
1
H nmr of 51 
 
 
Figure 28. Mass spectrum of 51 
  
M+. + H+ 
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Chapter 3 
Photophysical Evaluation   
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3. 1 Introduction to Photophysical Evaluation 
 
The driving force behind the synthesis of compounds 15 – 19 was the generation of novel, more 
efficient and potentially selective photodynamic agents for use in PDT. Currently in the UK 
alone there are over 260 new photosensitisers in clinical trials for potential application in 
PDT.
[9]
 It is of great importance therefore, to have some degree of selection process whereby 
only the very strong candidates will progress to clinical trials. This can be achieved through the 
photophysical evaluation of test compounds. From chapter 2, it was concluded that only 
compounds 15 and 16 were pure and efficiently uncomplicated in their synthesis to allow for 
further investigation. By the collection of the absorbance and emission spectra of the two 
compounds the appropriate wavelength of light required for the PDT process can be determined, 
as well as gaining some information regarding the relaxation process of the excited fluorophore. 
Finally, the compounds will be investigated as potential singlet oxygen generators. It is 
imperative that the new PDT agents have the ability to generate sufficient phosphorescence in 
order to transform the surrounding molecular oxygen into the cytotoxic reactive species that has 
the ability to destroy the damaged tissue as this underpins the PDT mechanism. 
 
3.2 Absorbance Measurements for Compounds 15 and 16 
 
The absorbance spectra for each of the two novel photosensitisers were recorded in isopropyl 
alcohol (IPA) and the maximum wavelength determined. The spectrum for 15 is displayed in 
Figure 29 and 16 in Figure 30. The absorbance spectrum is as expected with little difference 
between the two compounds. Each compound has a rather broad absorbance spectrum; this 
would be as expected from the rather large conjugated area with the absorbance being red 
shifted to a maxima value greater than 600 nm. Both Figures 29 and 30 display an absorbance 
from the compounds at a wavelength as far shifted as 700 nm. This wavelength would be 
suitable for deeper tissue penetration than ordinarily used from PDT. 
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Figure 29. Absorbance spectrum of 15 in IPA, absorbance maxima 660 nm. 
 
 
Figure 30. Absorbance spectrum of 16 in IPA, absorbance maxima 625 nm. 
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3.3 Emission Measurements for Compounds 15 and 16 
 
Compounds 15 and 16, as previously mentioned, contain an extended area of conjugation. This 
is typical for compounds capable of behaving as chromophores as it allows for effortless 
transitions between the electronic orbitals (n - π* and π – π* transitions) as they contain 
relatively close packed band gaps. The emission spectrum attributed to the photosensitiser 
compounds will therefore be of interest in the determination of PDT agent efficacy.  
In section 1.2 the mechanism of action for the transformation of molecular oxygen to the 
reactive oxygen species, singlet oxygen, is discussed. The requirements for the photosensitiser 
compound to undergo intersystem crossing and have an electron in the excited triplet state is 
paramount in the production of the cytotoxic agent. Evidence that the compound reaches the T1 
state would be if the compound emitted phosphorescence. Phosphorescence is much more 
difficult to measure than fluorescence due to the differences in lifetimes of the two radiative 
pathways. The lifetime of fluorescence emission is generally between 0.5 – 20 nanoseconds 
where as the lifetime of a compounds phosphorescence can be anywhere ranging from 
milliseconds up to several hours. The fluorescence emission spectrum achieved will give an 
indication of the compounds ability to fluoresce and indirectly its ability to phosphoresce. 
Figure 31 displays the emission spectrum for a solution of 15 in IPA excited at a wavelength of   
650 nm with Figure 32 displaying the emission spectrum of compound 16. It can be concluded 
from the two spectra that neither compound effectively fluoresces.  
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Figure 31. Emission spectra of 15 excited by fluorescence at 650 nm in IPA  
Figure 32. Emission spectra of 16 excited by fluorescence at 650 nm in IPA   
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3.4 Singlet Oxygen Generation 
 
The efficiency of the photosensitisers 15 and 16 as potential PDT agents can be determined by 
their ability to generate singlet oxygen. There are a number of ways to quantitatively measure 
the production of singlet oxygen. Singlet oxygen has an emission wavelength of 1280 nm
[54]
 and 
therefore can be directly detected with the appropriate spectrometer and filters. However, 
chemical trapping is the most common and sensitive technique used in the quantitative 
determination of this excited species.
[55]
 These chemical traps are varied in structure and form a 
new species when in direct contact with singlet oxygen in an equimolar ratio. The detecting 
parameter is generally light, for example, fluorescence, as in the case for 2,7 
dichlorodihydrofluorescein diacetate (DCFH-DA) , which has no fluorescence until it becomes 
oxidised by singlet oxygen to the fluorescent 2,7 dichlorofluorescein (DCF), Scheme 15.
[56]
 The 
increase in emission is monitored at 525 nm.  
 
 
Scheme 15. Deacetylation and oxidation of DCFH-DA (non fluorescent) resulting in the 
fluorescent DCF following reaction with singlet oxygen. 
 
The second common light-based parameter for the detection of singlet oxygen is absorbance, as 
discussed in section 1.2.2 DBDF 3 has a maximum excitation wavelength of 410 nm, this is 
illustrated in the absorbance spectra of 3 displayed in Figure 33.  
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Figure 33. Absorbance spectra of compound 3, displaying the absorbance maxima at 410 nm. 
Spectra recorded in Isopropyl alcohol. 
 
In the presence of singlet oxygen, the DBDF reacts via a 1,4 Diels-Alder reaction, leading to the  
furan ring system becoming destroyed and a significant degree of conjugation being lost within 
the compound resulting in a newly formed di-ketone molecule (Scheme 16). The distinctly 
different structure has blue shifted absorbance maxima. The depletion of the 410 nm band is 
directly proportional to the amount of singlet oxygen present in the solution. By monitoring the 
absorbance of 3 at 410 nm in the presence of the photosensitiser and an appropriate light source 
the amount of singlet oxygen generated can be determined. 
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Scheme 16 . Reaction of 3 with singlet oxygen, oxidised via a 1,4 Diel- Alder addition reaction 
resulting in a di-keto product with no absorbance at 410 nm.  
 
The singlet oxygen generation of photosensitisers 15 and 16 was determined using the 
quantitative singlet oxygen dependence absorbance of 3.  
 
3.4.1 Singlet Oxygen Quantum Yield 
 
The quantum yield for singlet oxygen generation, ΦΔ, is a measure of how efficient a 
photosensitiser generates singlet oxygen.
[57]
 If every photon absorbed by a photosensitiser leads 
to a molecule of singlet oxygen being created by energy transfer, then ΦΔ = 1. If no absorbed 
photon leads to a the creation of a molecule of singlet oxygen then ΦΔ = 0.
[12]
 The values of ΦΔ 
vary between different photosensitisers, solvents and are affected by pH.
[57] 
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A known photosensitiser, methylene blue 53 was chosen as a reference compound for singlet 
oxygen generation. Methylene blue has a rather long excitation wavelength and a recorded 
singlet oxygen quantum yield of 0.52 in D2O.
[58]
 
1O2
 64 
 
3.4.2 Light Sources for Excitation 
 
A number of different light sources were investigated for the quantitative determination of 
singlet oxygen. The light source requires an emitting wavelength in the region of 600 nm, while 
also ensuring that it causes minimal depletion to the furan signal at 410 nm in the absence of 
any photosensitiser. Prior to any light source being investigated using compound 3, the amount 
of depletion of the furan had to be established in dark conditions, the results of which are 
displayed in Figure 34. It was concluded from this experiment carried out in complete darkness 
that there is no significant depletion of the furan over the time period tested under dark 
conditions.   
 
 
 
 
Figure 34. Absorbance spectra of 3 (5 x 10
-5
 M) in isopropyl alcohol in dark conditions with 
samples taken every 5 min for 1 hr. 
 
The first light source to be considered was regular unfiltered white light, the wavelength range 
is generally in the region of 400 -700 nm. It can be seen from Figure 34 that there is a 
significant depletion in the amount of absorbed light at 410 nm for compound 3 in the absence 
of any photosensitiser.  
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Figure 35. Absorbance spectra of 3 (5x10
-5
 M ) in isopropyl alcohol (50 mL) in white light with 
samples taken every 5 min for 1 hr 
 
This is not wholly unexpected as the wavelength range of white light is so broad that compound 
3 is most likely decomposing photochemically as some of the white light is being absorbed by 
the compound. It can be concluded from Figure 35 that any investigation into the generation of 
singlet oxygen using compound 3 as a chemical trap must be carried out in dark conditions with 
the sample being subjected to light of a particular wavelength.  
 
After a number of different light sources were investigated, including red light bulbs and red 
Light emitting Diodes (LEDs) (see Appendix 2), it was decided that the most appropriate light 
source was that from a Carey Fluorescent Spectrometer with an additional fibre optic cable 
attached to allow for the fine tuning of excitation wavelength. This ensured that the most 
appropriate wavelength, as determined from Figures 29 and 30, was used for the excitation of 
compounds 15 and 16. 
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3.4.3 Control Experiments for Singlet Oxygen 
 
Further to the investigation into different light sources and experimental conditions, the initial 
requirement for the investigation into singlet oxygen generation from compounds 15 and 16, 
synthesised in this thesis, was to establish a control experiment. This experiment allows for the 
verification of the technique of measurement as well as generating a reference compound which 
has an already established singlet oxygen quantum yield, allowing for a direct comparison to be 
made with compounds 15 and 16. 
 
As discussed in some detail in chapter one, there is a large number of different types of 
compounds available to use as photosensitisers. Currently the most widely approved 
photosensitiser specific for use in photodynamic therapy is Photofrin, a purified derivative of 
the monomer hematophorphyrin 2. Hematoporphyrin was tested as a control substance, 
however, it proved to be difficult to work with as the absorbance had some degree of 
overlapping with the absorbance of the singlet oxygen chemical trap, compound 3 (see 
Appendix 3) as well as displaying poor repeatability. This is most likely due to the ease of 
hydrolysis of this compound as well as the lack of dimers and oligomers in the purchased 
compound.  
 
A more successful control compound was methylene blue. Methylene blue (52) has many 
diverse uses; it has been used as redox indicators, chemical dyes and as an antimalarial drug
 [59]
 
as well a photosensitiser compound for use in PDT
[60]
.  
 
As mentioned previously the singlet oxygen quantum yield (ΦΔ) of an individual compound is 
likely to be dependent on solvent systems, reaction conditions as well as techniques used in the 
measurement. With this in mind it was imperative that the generation of singlet oxygen was 
determined using our measurement technique for a known photosensitiser, such as methylene 
blue. For the purpose of this thesis the ΦΔ of methylene blue was taken as 0.52. The absorbance 
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spectrum of methylene blue is displayed in Figure 36. It can be seen from the spectra that there 
is little absorbance in the region of the singlet oxygen trapping compound 3 (410 nm) with the 
maximum absorbance occurring at the red region of the spectrum around 670 nm.  
 
 
Figure 36. Absorbance Spectrum of methylene blue showing the absorbance maxima at ~ 670 
nm with minimal absorbance at 410 nm.  
 
A control experiment using methylene blue and 3 in a 10:1 molar ratio with the absence of 
excitation wavelength was executed. As expected there is little derivation of the absorbance of 
the furan at 410 nm, this is displayed in Figure 37. 
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Figure 37. Control experiment using methylene blue and Compound 3, 10 :1 molar ratio in 
EtOH:water 1:1 (vol:vol), experiment carried out in darkness. 
 
However, when the same experiment was carried out under similar conditions but in the 
presence of the fibre optic light source set at an excitation wavelength of 660 nm, the depletion 
of the absorbance at 410 nm is much more pronounced. This is attributed to the formation of 
singlet oxygen produced by the methylene blue and the furan (3) being depleted following the 
mechanism shown in Scheme 3.2. 
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Figure 38. Depetion of absorbance of compound 3 due to the formation of singlet oxygen. 
Methylene blue and Compound 3, 10 :1 molar ratio in EtOH:water 1:1 (vol:vol), experiment 
carried out with an excitation wavelength of 660 nm. 
 
For ease of view the information from Figure 38 is displayed in Figure 39 showing the 
absorbance at 410 against time. This absorbance depletion at 410 nm can then be directly 
transferred into the quantum yield of singlet oxygen for comparison with compounds 15 and 16. 
 
 
Figure 39. Relative depletion in absorbance comparing Methylene Blue and 3 without light (top 
line) excitation wavelength 650 nm (Bottom line) 
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3.4.4 Singlet Oxygen Generation for Compounds 15 and 16 
 
Following similar procedures to that followed for the control experiment using methylene blue, 
compounds 15 and 16 were investigated for potential singlet oxygen generation using 
compound 3 as the chemical trap. One of the main differences between the novel 
photosensitisers prepared in this thesis and methylene blue is the differences in solubility. 
Methylene blue contains a positive charge and as such is readily water soluble, compound 15 
and 16 are neutral compounds and therefore have to be solubilised in Isopropyl alcohol for the 
study.  
The depletion of 3 in Isopropyl alcohol with 15 (Figure 40) and the depletion of 3 with 
16 (Figure 41) is shown. It is clear from these two graphs that the depletion observed for 3 with 
15 and 16 is minor when compared to the depletion observed when methylene blue was used 
(Figure 38). 
 
 
Figure 40. Absorbance of compound 3 with 15, 10 :1 molar ratio in Isopropyl, experiment 
carried out with an excitation wavelength of 650 nm.  
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Figure 41. Absorbance of compound 3 with 16, 10 :1 molar ratio in Isopropyl, experiment 
carried out with an excitation wavelength of 650 nm. 
 
The relative absorbance at 410 nm for 15 and 16 compared against the absorbance at 410 nm 
without any photosensitiser is shown in Figure 42 and Figure 43 for 15 and 16 respectively. 
Both show a slight depletion in absorbance at 410 nm when compared to the control, with the 
depletion of absorbance using 16 slightly more pronounced than 15. This could be due to 16 
being more solouble than 15 and indicate more phosphorescence being generated. 
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Figure 42. Relative depletion in absorbance comparing 3  without 15 (top line) and with 15 
(bottom line) excitation wavelength of 650 nm 
 
 
Figure 43. Relative depletion in absorbance comparing 3 without 16 (top line) and with 16 
(bottom line) excitation wavelength of 650 nm 
 
Methylene blue depletes the absorbance of 3 at 410 nm by 30.2% (Figure 38). If we take this 
depletion to indicate a quantum yield (ΦΔ) of 0.52 then the quantum yield of 15 and 16 can be 
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depletion of 3  in Figures 40 and 41 the quantum yields (ΦΔ) for 15 and 16 in isopropyl alcohol 
are 0.01 and 0.04, respectively.     
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In this thesis, the successful synthesis of target compounds 15 and 16 for investigation as 
photosensiters is reported. The synthesis of these compounds is discussed and presented 
allowing for full structural elucidation of the intermediates 22, 23 (see 2.3.1) and 32, 33 (see 
2.3.2) for the complete synthesis of 15 and 16 respectively. The absorbance maxima for both 
these compounds was found to be within the desired range 600 – 900 nm as would be expected 
for compounds with such a high degree of conjugation. Neither 15 nor 16 showed any 
fluorescence emission (see section 3.3) and tests for singlet oxygen generation were carried out 
using the singlet oxygen scavenger 3 to assess whether the compounds were able to excite 
molecular oxygen by energy transfer. The values of quantum yield (ΦΔ) of singlet oxygen 
generation were obtained and found to be 0.01 and 0.04 for 15 and 16 respectively. These 
values were extrapolated from comparison of the depletion at 410 nm of 3 using methylene 
blue, known to have a quantum yield of 0.52. It is evident from these values that when 
compared to the known photosensitiser the values for 15 and 16 are small. One possible 
explanation for this could be due to the poor solubility of these compounds, since the compound 
which has the best solubility, 16, is the one that has the higher quantum yield. If there are fewer 
molecules in solution due to this lower solubility a more powerful light source such as a filtered 
lamp may give improved results that show an increased difference between 15 and 16.  
 
Another possibility is that there was not a sufficient concentration of molecular oxygen 
dissolved within the solvent for 15 and 16 to generate singlet oxygen. The synthesis of more 
water-soluble compounds would enable the used of solvents that contain a higher level of 
dissolved oxygen and mimic more accurately physiological conditions.  
 
The chelation of 16 with boron was attempted in the hope that the product 17 would be 
structurally more stable and more efficient at reaching the T1 state due to minimizing loss of 
energy by collisions of molecules in solution.  
 
 76 
 
Due to time constraints target compounds  18 and 19, designed to include parameter specific 
receptors, were unable to be synthesised. To create a photosensitiser with a pyridine group as a 
receptor (as in compound 18) the synthesis of three different chalcones were attempted - 45, 46 
& 48. After attempting various reaction conditions, the synthesis of 45 was successful with the 
characterisation of this compound discussed in section 2.3.4. However, due to the mimimal 
yield of 45, a scale-up of this intermediate compound would be required in future work to 
provide enough substrate for the next two steps in the complete synthesis of 18 before any 
photophysical evaluation could be carried out. 
The first step in the synthesis of 18 proved difficult to drive to completion, indicating 
that different reaction conditions would be needed to give enough of intermediate 51 that could 
be purified and still leave a realistic amount to for further synthesis. The disadvantage of this 
synthesis was the expense of the starting material, limiting the number of potential reaction 
pathways that could be investigated.       
 
The next logical step in the development of this research would be to incorporate a halogen, 
such as bromine (Figure 44), to 15 and 16 to investigate if there is an increased 
phosphorescence emission that could be caused in theory by the ―heavy-atom effect‖, of which 
the mechanism is still not understood.  
 
NH
N
N NH
N
N
BrBr
benzene
Br2
 
 
Figure 44. Bromination of 15 in benzene 
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It can be concluded from the investigation carried out in this thesis that the photosensitisers 
deigned and synthesised in this thesis did indeed increase the potential wavelength of PDT 
application. However, the quantum yield of singlet oxygen is too low to merit further 
investigation on these compounds without further modification, such as those discussed above. 
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Chapter 5 
Experimental Techniques 
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5.1 Experimental techniques 
 
NMR  
1
H NMR spectra were obtained on a Brucker (400 MHz) NMR spectrophotometer. Samples 
were dissolved ~15 mg in 2 mL of CDCl3 unless otherwise stated. All samples were run at room 
temperatire with the samples being spun at 20 rpm. 
 
Mass spectrometry 
An Aligent Technologies 6100 Single Quadrupole LC/MS was used to obtain positive and 
negative electrospray spectra. Samples were dissolved in a concentration not exceeding 1 mg/ 1 
mL in MeOH and direct infusion onto the instrument. 
 
Chromatography 
Thin layer chromatography was carried out on Macherey-Nagel 60 UV254 plates. Compounds 
absorbed in the visible region with additional visualisation, were required, carried out by using 
short-wavelength UV light.   
Flash chromatography was carried out in columns packed with silica gel (silica 60, Alfa Aesar), 
70-230 mesh with the mobile phase being varied accordingly. 
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5.2 Synthetic Procedure for Individual Compounds 
 
22 (E)-3-(biphenyl-4-yl)-1-phenylprop-2-en-1-one 
 
To biphenyl-4-carboxaldehyde (2.5 g, 13.0 mmol) stirring in ethanol (7.4 mL) acetophenone 
(1.4 mL, 11.0 mmol) was added followed by NaOH (0.67 g) in H2O (3.7 mL) and left stirring at 
RT for 24h. Addition of 1M HCl revealed a precipitate which was filtered and dried in oven 
under vacuum at 50 °C. Crude yield 95.5 % Purification by column chromatography on silica 
eluting with EtOAc/Hexane (15:85) gave the chalcone yield 80% 
1
H NMR (CDCl3) δ: 8.06-8.04 
(m, 2H, Ar-H), 7.87 (d, J = 15.7 Hz, 1H, Trans-H), 7.89-7.85 (m, 2H, Ar-H), 7.68-7.59 (m, 5H, 
Ar-H), 7.59 (d, J = 15.8 Hz, 1H, Trans-H), 7.54-7.46 (m, 4H, Ar-H), 7.41-7.37 (m, 1H, Ar-H) 
13
C NMR (CDCl3) δ: 190.5, 144.4, 143.3, 140.1, 138.3, 133.9, 132.8, 129.0, 128.9, 128.7, 128.5, 
127.9, 127.6, 127.1, 121.9, m/z calculated, 285.12 found 285.1 
 
23 3-(biphenyl-4-yl)-4-nitro-1-phenylbutan-1-one 
 
A 50 mL round-bottomed flask was charged with 22 (2.0 g, 7.04 mmol) in methanol (1 mL) and 
diethylamine (1.8 mL, 35 mmol) then stirred at RT while nitromethane (2.4 mL, 36 mmol) was 
added and the reaction brought to reflux at 90 °C for 24 h. 1M HCl added and the precipitate 
was filtered and dried over night in a vacuum oven at 50 °C. This afforded a brown solid, yield 
86 % 
1
H NMR (CDCl3) δ: 7.86-7.84 (m, 2H, Ar-H), 7.49-7.45 (m, 5H, Ar-H), 7.39-7.32 (m, 4H, 
Ar-H), 7.28-7.25 (m, 3H, Ar-H), 4.80 (dd, J = 6.6 Hz, 12.5 Hz, 1H, CHNO2), 4.66 (dd, J = 8.0 
Hz, 12.5 Hz, 1H, CHNO2), 4.23-4.16 (m, 1H, CHCH2NO2), 3.46 (dd, J = 6.4 Hz, 17.7 Hz, 1H, 
CHCO), 3.40 (dd, J = 7.4 Hz, 17.7 Hz, 1H, CHCO)
 13
C NMR (CDCl3) δ: 195.8 (C=O), 139.7 
(CIV), 139.4 (CIV), 137.1 (CIV), 135.3 (CIV), 132.6 (CH), 127.8 (CH), 127.7 (CH), 127.0 (CH), 
126.9 (CH), 126.7 (CH), 126.4 (CH), 126.0 (CH), 78.5 (CH2), 40.5 (CH2), 37.9 (CH), m/z 
calculated 345.39, found 345.2 
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15(Z)-3-(biphenyl-4-yl)-N-(3-(biphenyl-4-yl)-5-phenyl-2H-pyrrol-2-ylidene)-5-phenyl-1H-
pyrrol-2-amine 
 
A 50 mL round-bottomed flask was charged with 23 (166 mg, 481 mmol) dissolved in Butan-1-
ol (20 mL), ammonium acetate (1.30 g, 17 mmol) in butan-1-ol (5 mL) added and refluxed at 
117 °C for 48 h, concentrated on rotary evaporator and filtered. Washed with ethanol and dried 
in oven overnight at 50 °C under vacuum. 
1
H NMR (CDCl3) δ: 8.26-8.24 (m, 4H, aryl-H), 7.60-
7.59 (m, 7H, Ar-H), 7.52-7.50 (m, 4H), 7.42-7.39 (m, 8H), 7.36-7.31 (m, 6H), 7.27-7.24 (m, 
2H),  m/z calculated 602.25, found 602.20  
 
 
32 (E)-3-(biphenyl-4-yl)-1-(4-methoxyphenyl)prop-2-en-1-one 
 
A 50 mL round-bottomed flask was charged with biphenylcarboxaldehyde (1.22 g, 6.7 mmol), 
4-methoxyacetophenone (1.0 g, 6.7 mmol) added to ethanol: water (11.4 mL: 2 mL). Then KOH 
(0.01 g, 0.2 mmol) added and left stirring at RT. After 24 h a white precipitate formed which 
was filtered off and dried in oven under vacuum overnight. 
1
H NMR (CDCl3) 8.07 (d, J = 8.9 
Hz, 2H, Ar-H), 7.85 (d, J = 15.6 Hz, 1H, Trans-H), 7.73 (d, J = 8.3 Hz, 2H, Ar-H), 7.66 (d, J = 
8.3 Hz, 2H, Ar-H), 7.64-7.63 (m, 2H), 7.60 (d, J = 15.6 Hz, 1H, Trans-H), 7.49-7.46 (m, 2H, 
Ar-H), 7.40-7.37 (m, 1H, Ar-H), 7.01-6.99 (m, 2H, Ar-H), 3.90 (s, 3H, CH3O) 
13
C NMR 
(CDCl3) δ: 163.8, 143.9, 143.4, 140.5, 134.4, 131.5, 131.2, 129.2, 128.2, 127.9, 127.4, 122.0, 
114.2.  
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33 3-(biphenyl-4-yl)-1-(4-methoxyphenyl)-4-nitrobutan-1-one 
 
32 (500 mg, 1.6 mmol) was dissolved in methanol (4.8 mL) and diethylamine (0.4 mL, 8 mmol) 
then nitromethane (0.55 mL, 8 mmol) was added while stirring at RT. The reaction was brought 
to relfux at 90 °C and left stirring for 24 h. Upon cooling a brown solid precipitated, 1M HCl 
was added and the solid was filtered. The dried precipitate weight was 458 mg. 
1
H NMR 
(CDCl3) δ: 7.94-7.90 (m, 2H, Ar-H), 7.56-7.54 (m, 4H, Ar-H), 7.55 (d, J = 8.3 Hz, 2H, Ar-H), 
7.45-7.41 (m, 3H, Ar-H), 7.37-7.34 (m, 2H, Ar-H), 6.95-6.91 (m, 2H, Ar-H), 4.87 (dd, J = 12.5, 
6.5 Hz, 1H, CH2NO2), 4.72 (dd, J = 12.5, 8.2 Hz, 1H, CH2NO2), 4.27 (m, 1H, CHCH2NO2), 
3.87 (s, 3H, CH3O), 3.47 (dd, J = 17.5, 6.4 Hz, 1H, CH2CO), 3.39 (dd, J = 17.5, 6.4 Hz, 1H, 
CH2CO) 
 
16 (Z)-3-(biphenyl-4-yl)-N-(3-(biphenyl-4-yl)-5-(4-methoxyphenyl)-2H-pyrrol-2-ylidene)-5-(4-
methoxyphenyl)-1H-pyrrol-2-amine 
 
 A 50 mL round-bottomed flask was charged with 33 (0.2 g, 0.53 mmol), ammonium acetate 
(1.46 g, 19 mmol) and butan-1-ol (2 mL) and stirred under reflux at 117 °C. After 48 h the 
reaction mixture was allowed to cool, the deep purple precipitate was filtered and washed in 
ethanol. 
1
H NMR (CDCl3) δ: 8.18 (d, 2H, Ar-H), 7.92 (d, 2H, Ar-H), 7.69-7.67 (m, 4H, Ar-H), 
7.48 (m, 4H, Ar-H), 7.21-7.19 (m, 2H, Ar-H), 7.07 (m, 2H, Ar-H), 3.93 (s, 3H, OCH3)   
 
171,9-di(biphenyl-4-yl)-5,5-difluoro-3,7-bis(4-methoxyphenyl)-5H-dipyrrolo[1,2-c:1‘,2‘-
f]triazaborinin-4-ium-5-uide 
 
To a 50 mL round-bottomed flask 16 (14 mg, 0.02 mmol) was dissolved in dry DCM (4 mL) 
under N2. BF3OEt2 (0.1 mL, 0.8 mmol) in dry DCM (1 mL) was prepared, then 0.2 mL of this 
dilution was added to 16 while stirring under N2. Then diisopropylethylamine (0.01 mL, 0.06 
mmol) added and the reaction left under N2 for 24 h at RT. The reaction was washed with 2 × 
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50 mL of H2O, then the organic layer separated and dried over Na2SO4 before dried in oven 
under vacuum overnight. Weight of solid, 13 mg.  
 
45 (E)-1-phenyl-3-(pyridine-4-yl)prop-2-en-1-one 
 
Method 1: 
A 100 mL round-bottomed flask was charged with 4-pyridine carboxaldehyde (1.0 mL, 10.6 
mmol) and acetophenone (1.3 mL, 10.6 mmol) in H2O (30 mL) and stirred at RT. Then 10% 
Na2CO3 (4mL) was added and the reaction was monitored by TLC. Disappearance of 
acetophenone was faint, reaction was left overnight after which there was no precipitate. TLC 
with (DCM/ MeOH 1%) showed that there was still starting material unreacted. Ethanol (5 mL) 
was added and monitored by TLC, after 3 h a precipitate had formed. The precipitate was 
purified by preparative TLC using EtOAC as the eluent.  
 
Method 2: 
A 100 mL round-bottomed flask was charged with 4-pyridine carboxaldehyde (2.3 mL, 18.7 
mmol) and acetophenone (2.3 mL, 18.7 mmol) were added to a mixture of ethanol: water (9 
mL: 53 mL) at RT, then 10% K2CO3 (2 mL) was added. After 3 h no precipitate had formed and 
the reaction was left overnight. A preparative TLC using Hexane:DCM 50:50 gave a crude 
product in a small yield.  
 
 
Method 3:  
To a 100 mL round-bottomed flask charged charged with NaOH (80 mg, 2 mmol) in H2O (13.3 
mL) and ethanol (2.3 mL), 4-pyridine carboxaldehyde (500 mg, 4.67 mmol) was added at RT. 
Then acetophenone (560 mg, 4.67 mmol) was added and after 8 h a precipitate had formed. This 
was then purified on a column with SiO2 using toluene: EtOAc 50:50 as the eluent. 
1
H NMR 
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(CDCl3) δ: 8.61-8.60 (m, 2H, ortho Ar-H), 7.95 (d, J = 7.3 Hz, 2H, ortho Ar-H), 7.60-7.59 (m, 
2H), 7.53 (t, J = 7.4 Hz, 1H, para Ar-H), 7.46-7.38 (m, 4H), m/z calculated 210.08, found 210.0   
 
 
Method 4: 
 
Into a solution of 10 % KOH (30 mL) at O°C 4-pyridine carboxaldehyde (1.22 mL, 10 mmol) in 
EtOH (10 mL) was added and allowed to stir for 15 min. Then acetophenone (1.24 mL, 10 
mmol) added dropwise over a period of 10 min. The reaction mixture was left in the ice bath for 
5 h then the mother liquor poured through a Buchner funnel, the resulting yellow precipitate 
was isolated: 1 g.  
  
46 (E)-1-(4-methoxyphenyl)-3-(pyridin-4-yl)prop-2-en-1-one 
                                                   
A 50 mL round-bottomed flask was charged with 4-pyridine carboxaldehyde (0.5 mL, 5.3 
mmol) in a stirred solution of Na2CO3
.
H2O (303 mg, 1.1 mmol) in H2O (10.6 mL). Then 4-
methoxyacetophenone (796 mg, 5.3 mmol) was added and the reaction was stirred at RT for 
24h. 
 
52 (E)-3-(2,3,5,6,8,9,11,12-octahydrobenzo[b][1,4,7,10,13]pentaoxacyclopentadecin-15-yl)-1-
phenylprop-2-en-1-one 
 
Method 1: 
A solution of 4‘-formylbenzo-15-crown-5 (0.2 g, 0.68 mmol) in ethanol (1 mL) was added 
gradually to an aqueous solution of 10% KOH (3 mL) at 0°C for 15 min. Acetophenone (0.084 
mL, 0.68 mmol) added slowly dropwise and the mixture was then allowed to attain room 
temperature (25°C) and stirred for 24 h, then the flask placed in the fridge overnight. 1M HCl 
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added, extracted using DCM and the organic layer dried using Mg2SO4 and concentrated on the 
rotary evaporator. Crude weight 0.169 g 
 
 
Method 2: 
Acetophenone (81 mg, 0.7 mmol) added to KOH 10% (3 mL) at O°C and stirred for 15 min. 
Then 4‘-formylbenzo-15-crown-5 (200 mg, 0.68 mmol) added and the reaction was stirred for 
15 min, then allowed to reach RT and stirring continued for 4 h. The flask was placed in a fridge 
overnight, 1M HCl was added and the precipitate was filtered.  
 
50 2,3,5,6,8,9,11,12-octahydrobenzo[b][1,4,7,10,13]pentaoxacyclopentadecine-15-carbaldehyde 
 
Benzyl-15-crown-5 (200 mg, 0.75 mmol) and DMF (0.35 mL) added to flask purged with 
nitrogen- flask in ice bath for 10 mins. POCl3 added dropwise (0.13 mL) slowly. Flask left for 1 
min then allowed to reach RT and reaction stirred for 16 h. Then heated to 60 °C for 1 h and 
allowed to cool. The reaction mixture was added to 1.2 g of ice, flask rinsed with 0.2 mL water. 
The combined solution brought to pH 7 with saturated K2CO3. Extracted in chloroform (2x1.2 
mL) dried with MgSO4 and allowed to stand for 1 h, then pipetted into flask and concentrated 
by rotary evaporator. Crystals formed, showed starting material.  
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Appendix 1- 
Methods for Synthesis of  
Compound 45 
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Method 1 (solvent used- H2O):  
 
The synthesis was carried out using the method reported in the paper, using water as the only 
solvent 
[53]
. Monitoring the reaction by TLC (DCM/ 1%MeOH) there was only faint 
disappearance of the acetophenone spot, even after 24 h when the paper reported that the 
disappearance should occur within a few hours. When a TLC of an aliquot of the reaction 
mixture was taken the organic and aqueous layers were separated. The organic layer gave a 
strong spot for acetophenone and 3 other bands close together, the aqueous layer also contained 
a spot for acetophenone and 3 very faint spots relating to the spots in the organic layer.   
 
Ethanol was then added to improve the solubility of the reactants and monitored by TLC. After 
1 h the TLC still contained starting material but after a further 3 h a bulky yellow precipitate and 
a fluffy white precipitate had appeared. These two precipitates were filtered and compared by 
TLC using EtOAc. There were matching bands with varying degrees of intensity, showing that 
there was mix of the same products in both precipitates.  The yellow precipitate was further 
dried in a vacuum oven and turned into an oil. This was dissolved in DCM and a preparative 
TLC was ran in EtOAc. There were three bands; the first corresponded to acetophenone, the 
second contained a mixture of  acetophenone and 4-pyridine carboxaldehdye, the third 
contained a mix of compounds with peaks in the aromatic region differing from the starting 
materials.   
 
Method 2 (solvent used- H2O + ethanol): 
 
When the reaction was repeated the conditions were changed to have a 1:6 ethanol:H2O ratio. 
Again though within 3 h no precipitate had formed, so the reaction was left to occur over night. 
A small sample of 2 mL was taken of the mother liquor, which was acidified (1M HCl) and the 
aqueous layer was extracted, then NaOH 1M was added and the organic layer was extracted in 
DCM. The TLC of the organic layer showed faint starting material plus a third band. This 
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procedure was adapted for the whole reaction mixture. The organic layer was dried and a 
column was performed using DCM as the eluent, however this was far too polar and separation 
of the products was not achieved. The collected crude product was instead purified using 
preparative TLC with Hexane:DCM 1:1, to reveal a band which gave off fluorescence under the 
long range UV. It was hoped this band would correspond to the product of the reaction which 
would be expected to absorb UV of this wavelength. The 
1
H nmr of this band did not show any  
starting material and the intergration, multiplicity and shift of the peaks were in accordance with 
what would be expected from the spectrum of the product.  
 
Method 3 (NaOH used as base instead of K2CO3):  
 
The majority of the reaction mixture did contain starting material so the usefulness of the above 
method for synthesising an intermediate was limited. In an effort to increase the conversion of 
the reactants to the chalcone, NaOH was used in place of K2CO3 (10%) or Na2CO3 (10%). Since 
the hydroxide is a stronger base than the carbonate it was hoped that there would be more 
enolate formed to push the reaction forward. When NaOH was used a precipitate did form when 
using a similar ratio of ethanol to water that was already attempted with the previous base.  
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Appendix 2- 
Red LED Light Source 
Spectra 
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A red LED light was used as the light source for compounds 15 and 16 to exclude light of 
wavelength out with the 600-900 nm range. Figure 45 and Figure 46 show that there is no 
significant depletion of 3 with either compound. This could be attributed to the wavelength of 
light not having sufficient intensity to excite the sensitiser, inducing phosphorescence that 
would generate singlet oxygen . 
 
 
Figure 45. Absorbance spectrum of 3 (5x10
-5
M) in Isopropyl alcohol with 15 (5x10
-6
M), 
experiment carried out using red LED light source.  
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Figure 46. Absorbance spectrum of 3 (5x10
-5
M) in Isopropyl alcohol with 16 (5x10
-6
M), 
experiment carried out using red LED light source.  
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     Appendix 3- 
  Hematoporphyrin as  
    Control Photosensitiser Spectra  
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Figure 47. Absorbance of 3 with hematoporphyrin, in Isopropyl alcohol, 10 :1 molar ratio 
excited with white light.  
 
 
Figure 48. Absorbance of 3 with hematoporphyrin, in Isopropyl alcohol, 100 :1 molar ratio 
excited with white light. 
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